全文获取类型
收费全文 | 1341篇 |
免费 | 98篇 |
国内免费 | 8篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 58篇 |
妇产科学 | 19篇 |
基础医学 | 146篇 |
口腔科学 | 29篇 |
临床医学 | 201篇 |
内科学 | 267篇 |
皮肤病学 | 16篇 |
神经病学 | 81篇 |
特种医学 | 266篇 |
外科学 | 126篇 |
综合类 | 22篇 |
一般理论 | 1篇 |
预防医学 | 53篇 |
眼科学 | 16篇 |
药学 | 47篇 |
中国医学 | 6篇 |
肿瘤学 | 89篇 |
出版年
2024年 | 3篇 |
2023年 | 9篇 |
2022年 | 4篇 |
2021年 | 21篇 |
2020年 | 13篇 |
2019年 | 13篇 |
2018年 | 33篇 |
2017年 | 23篇 |
2016年 | 22篇 |
2015年 | 30篇 |
2014年 | 41篇 |
2013年 | 37篇 |
2012年 | 49篇 |
2011年 | 37篇 |
2010年 | 48篇 |
2009年 | 73篇 |
2008年 | 48篇 |
2007年 | 30篇 |
2006年 | 30篇 |
2005年 | 22篇 |
2004年 | 25篇 |
2003年 | 28篇 |
2002年 | 36篇 |
2001年 | 20篇 |
2000年 | 18篇 |
1999年 | 17篇 |
1998年 | 56篇 |
1997年 | 52篇 |
1996年 | 67篇 |
1995年 | 51篇 |
1994年 | 44篇 |
1993年 | 48篇 |
1992年 | 26篇 |
1991年 | 18篇 |
1990年 | 30篇 |
1989年 | 48篇 |
1988年 | 39篇 |
1987年 | 42篇 |
1986年 | 39篇 |
1985年 | 25篇 |
1984年 | 17篇 |
1983年 | 14篇 |
1982年 | 23篇 |
1981年 | 14篇 |
1980年 | 9篇 |
1978年 | 7篇 |
1977年 | 13篇 |
1976年 | 11篇 |
1975年 | 13篇 |
1965年 | 3篇 |
排序方式: 共有1447条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
M. Bertolotto G. Cecchini C. Martinoli R. Perrone G. Garlaschi 《European radiology》1996,6(5):637-639
A case of primary non-Hodgkin's lymphoma (NHL) of the mandible with unusual radiographic presentation is reported. The panoramic radiography revealed diffuse widening of the right mandibular canal with ill-defined margins and absence of edge sclerosis. Computed tomography showed infiltration of the superior portion of the canal with involvement of the vestibular cortex of the bone and of the alveolar ridge.
Correspondence to: M. Bertolotto 相似文献
4.
5.
6.
7.
8.
9.
The characteristics associated with non-attendance to mammographic breast cancer screening were studied by interviewing a random sample (213 attenders, 121 non-attenders in the 1989 screening) of residents in one of the municipalities of the Florence District Program, where screening has been ongoing since 1970. The overall attendance rate was 60%, and it was dependent on age (40-49 years, 66.5%; 50-59 years, 62.5%; 60-70 years, 55.5%), whereas a significant association with socio-economic status, educational level and health-behavior reported in other programs was not confirmed in the study. This finding suggests that determinants of non-attendance may vary and should be evaluated in each local setting. The belief that screening is useless, fear of cancer being detected, postponement and laziness were the most common motivations of refusal stated by non-attenders, and such a negative attitude towards screening was rather strong since most non-attenders stated they would not like to be informed or stimulated to attend future screenings. Rapid improvement of attendance rates in such a context might be achieved only by putting special pressure on women aimed to change their negative attitude towards screening and their opinion about the benefits of early breast cancer detection. This might be regarded as unacceptable and however would involve high costs and a major organization effort. 相似文献
10.